In the Breast International Group (BIG) 1–98 trial [43], including 6193 postmenopausal women with hormone receptor–positive early breast cancer, the use of cholesterol-lowering drugs, including statins, was associated with improved outcomes in postmenopausal patients with early-stage hormone receptor-positive breast cancer (HR 0.79 for disease-free survival). The gene discussed is NR4A1; the disease is breast carcinoma.